July is Sarcoma Awareness Month. Sarcomas are cancers that affect soft tissues, bones, and joints

Sarcoma Awareness Month: Comparative Oncology Clinical Trials

July is Sarcoma & Bone Cancer Awareness Month. Sarcomas are rare cancers. As a result, sarcomas don't get the attention or necessary research and funding that other more common cancers might get. This month is a good time to raise awareness of sarcomas and bone cancers and learn more about different types of sarcomas, risk factors, sarcoma research, and more.

About Sarcomas & Bone Cancers

Sarcomas are cancers that develop in connective tissues and may spread to other tissues or parts of the body. There are more than 70 different subtypes of sarcomas, but all sarcomas are divided into two main types: soft tissue sarcomas and bone cancers. Soft tissue sarcomas develop in muscles, fat, tendons, nerves, veins, arteries, or even within organs. These sarcomas are most often located in arms, legs, and the abdomen but can also occur in the head or neck. Bone cancers are found in bone or cells that form bone. Most bone cancers are found in long bones, such as leg or arm bones.

About 80 percent of all sarcomas are soft tissue sarcomas, and the remaining 20 percent are bone cancers. 13,000 people in the United States are diagnosed with soft tissue sarcomas each year, and 3,500 are diagnosed with bone cancers. Sarcoma cases account for about one percent of all new cancer cases.

Because sarcomas are fairly rare in humans, clinical trials and research to learn about sarcomas and find the best treatments are also less common. It can be difficult for researchers to not only find research participants but to get the same level of interest and funding that other more prevalent cancers might. As a result, an interesting field of research has been growing to advance sarcoma research: comparative oncology. 

About Comparative Oncology

Comparative oncology is the study of naturally occurring cancers in animals compared to those in humans in an effort to better understand the biology of disease, test new treatments, and find cures for humans and animals. This field brings together clinicians, veterinarians, and researchers to collaborate and improve health and outcomes for both humans and animals. Because the cancer studied in comparative oncology occurs naturally and spontaneously in animals rather than artificially in mice or other animals, studies are often more accurate and can make the drug development process faster. Some types of animals involved in this type of research are cats, horses, ferrets, and, most commonly, dogs.

Dogs are the most common animal in comparative oncology studies because humans and dogs share many similarities when it comes to cancer. Just like humans, dogs can develop brain, skin, lung, and bone cancers. Dogs also typically share the same living spaces as humans, so they are exposed to the same environmental factors that may cause cancer. Finally, humans and dogs often share the same genetic mutations that can lead to cancer as well as similar immune systems.

Sarcomas are much more common in dogs than in people, making comparative oncology a perfect fit for sarcoma research to benefit both dogs and humans. Other than the life stage at which sarcoma typically occurs due to dogs’ shorter lifespans, sarcomas in dogs and humans are virtually identical. 

Sarcoma Comparative Oncology Trials

One main focus of comparative oncology studies involving sarcomas is developing new treatments for dogs that may also apply to humans. In 2017, University of Minnesota researchers developed a new drug that improved survival rates in dogs with hemangiosarcoma (HSA), an aggressive sarcoma that is very similar to angiosarcoma in humans. The drug, eBAT, targets tumors and their vascular systems while causing minimal damage to the body’s immune system. 

The drug was tested on 23 dogs of various breeds and sizes with HSA of the spleen. The treatment improved the dogs’ six month survival rate to 70 percent. Five of the 23 dogs lived more than 450 days after receiving the treatment. This was a marked increase since typically only 50 percent of dogs with HSA live more than four to six months, and only 10 percent live for a year after diagnosis. Researchers hope studies like this will develop treatments that not only prolong life for dogs with sarcomas but can also quicken the drug development process for humans with similar types of sarcomas.

Another key part of sarcoma comparative oncology research is finding risk factors, including genetic patterns, for developing sarcomas and predicting how aggressive sarcomas may be, as well as determining prevention strategies. 

Researchers have also examined prevention strategies, risk factors, detection, and treatments for canine HSA through the Shine On Study. This study followed dogs over three phases. Phase One of the study developed and refined a blood test to accurately detect HSA in dogs. Phase Two continued to use the blood test to see if HSA could be detected in dogs whose disease had returned. In Phase Three, the blood test was used to develop risk profiles for dogs, and eBAT was used to both prevent and treat HSA. During Phase Three, 210 dogs continued to be followed. Researchers ultimately found that eBAT is safe for dogs. They also found that if a dog received a negative blood test, the risk of the dog developing HSA over the next six months is less than one percent.

As sarcoma research and its relationship with comparative oncology grows, more cancer centers and researchers are developing entire programs devoted to comparative oncology research. The Masonic Cancer Center has made this work a focus in recent years with the help of researchers from the University of Minnesota College of Veterinary Medicine. With the help of comparative oncology, researchers will continue to make an impact on sarcoma and other cancers in humans and animals.